MoSys Inc. (NASDAQ:MOSY)

MoSys Inc. (NASDAQ:MOSY) Spikes

MoSys Inc. (NASDAQ:MOSY)

MoSys Inc. (NASDAQ:MOSY) shares have spiked over 140%, to $1.60, on the back of massive volumes after the technology company reported Q3 2017 financial results. Volume has been huge. Currently, over 127 times the average share volume has traded today.

MoSys Inc. (NASDAQ:MOSY)

MoSys, Inc. (NASDAQ:MOSY) is a nano-cap ($5.4 million) fabless semiconductor company enabling leading equipment manufacturers of Cloud, networking, communications, and data center systems to address the continual increase in Internet users, data and services. The company’s solutions deliver data path connectivity, speed and intelligence while eliminating data access bottlenecks on line cards and systems scaling from 100G to multi-terabits per second.

MoSys Q3 Earnings

MoSys, Inc. (NASDAQ:MOSY)’s Q3 2017 net loss was $1.7 million, or ($0.22) per share, compared with a net loss of $4.0 million, or ($0.60) per share, for the previous quarter and a net loss of $4.7 million, or ($0.71) per share, for the same period in 2016. Total net revenue for Q3 2017 was $2.5 million, compared with $1.4 million for the previous quarter and $1.6 million for the third quarter of 2016. Product revenue for the third quarter was $2.2 million, compared with $1.1 million in the second quarter of 2017 and $1.2 million in the year-ago period.

Len Perham, President and CEO of MoSys, Inc. (NASDAQ:MOSY), “Our revenue growth in the third quarter was primarily driven by increased shipments to our largest Bandwidth Engine 2 customers. More specifically, the design wins with our lead security-appliance customer entered production in early 2017, and have been a significant driver of our increased revenue this past year. As part of our close collaboration with our lead customers, we have developed a solid backlog that extends out through 2018.”

MOSY Stock Performance

The consensus of analysts gave shares of MoSys, Inc. (NASDAQ:MOSY) a one-year price target of $2.00. That level has not been reached since late June, after which MOSY shares began a slide that saw the shares trade under the important $1 level for the majority of the trading sessions since the beginning of September.

MOSY shares have drastically underperformed the sector and market over the past year. Year-to-date MOSY shares are down over 70%. Over the past month, shares have dropped over 20%. Despite the poor performance, today’s spike has moved MOSY’s Relative Strength Index score to 83 – a figure well above the threshold normally considered for labeling a stock as “overbought”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $MOSY and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

FuelCell Energy Inc. (NASDAQ:FCEL)

FuelCell Energy Inc. (NASDAQ:FCEL) Short Interest Drops

FuelCell Energy Inc. (NASDAQ:FCEL)

FuelCell Energy Inc. (NASDAQ:FCEL) shares gained 4.52% in Friday’s trading session as short interest on the stock continued to drop. Over the past two weeks, short interest has dropped by 3.3% and currently accounts for 7.2% of the company’s total float.

FuelCell Energy Inc. (NASDAQ:FCEL)

Fuel Cell Technology

FuelCell Energy Inc. (NASDAQ:FCEL) has been on an impressive run – since June it has gained more than 100% in market value. However, for the full year, the stock is up by 15%. The stock is currently trading in an uptrend.

Growth in popularity of the company’s fuel cell technology appears to have strengthened investors’ confidence in the company’s long-term prospects. The technology utilizes a chemical reaction to convert a fuel source to electricity. Given its benefits and the fact that it is eco-friendly, the U.S Defense Department has started to use the technology.

General Motors has started working with the U.S army to develop fuel cell electric vehicles as the race to reduce dependence on conventional fuel gathers momentum. The rise in popularity of this technology has resulted in fuel cell producers like FuelCell attracting big contracts from customers across various sectors.

FuelCell Energy Inc. (NASDAQ:FCEL) has since entered into a power purchase agreement with the Connecticut Municipal Electric Energy Cooperative. The agreement is for the supply of power to the U.S Navy Submarine Base in Groton. The 7.4MW clean power is to be generated from the company’s two SureSource 400TM power plants.

The power project will ensure the U.S Navy has long-term cost-effective power for powering critical infrastructure. The fuel cell plants are also to be configured for grid-independent operations.

“Our fuel cell solutions are compelling as their predictable and clean power generation profile meets resiliency and environmental goals simultaneously. Additionally, this project is structured so that the U.S. Navy enjoys the many benefits of clean on-site power generation while continuing to work with its local and trusted utility under a pay-as-power-is-produced model,” said CEO Chip Bottone.

SureSource Certification

Separately, FuelCell Energy Inc. (NASDAQ:FCEL)’s SureSource 1500 fuel cell power plant operating on Anaerobic Digester Gas has received an important certification. The California Air Resources Board’s certification acknowledges the clean air profile of the solution, in facilitating air permitting process which reduces costs.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $FCEL and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Infinity Pharmaceuticals Inc. (NASDAQ:INFI)

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) Drops As Earnings Beat

Infinity Pharmaceuticals Inc. (NASDAQ:INFI)

Shares of Infinity Pharmaceuticals Inc. (NASDAQ:INFI) fell 13.93% after the company reported on its Phase 1 clinical data for IPI-549, an oral selective phosphoinositide-3-kinase-gamma targeting immune-suppressive tumor macrophages. Trial results indicate that the candidate drug was well tolerated and clinically active.

Infinity Pharmaceuticals Inc. (NASDAQ:INFI)

Clinical Trial Results

The sell-off on Infinity Pharmaceuticals Inc. (NASDAQ:INFI) stock comes as a surprise, given that the biopharmaceutical company is fresh from posting a narrower than expected third-quarter net loss. However, the stock is still trading in an uptrend despite coming under pressure in recent trading sessions. The stock is up by more than 60% for the year, as it continues to outperform the overall industry.

The positive IPI-549 and Q3 financial results should affect the stock’s direction of trade heading into the end of the year.

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) is evaluating IPI-549 as a monotherapy and in combination with Opdivo in patients with advanced tumors.

There is a significant need for better treatment options to take care of patients who do not respond to existing immunotherapies.

“In particular, patients with mesothelioma and adrenocortical carcinoma have limited effective treatment options, and our early evidence of activity suggests the potential for IPI-549 to improve outcomes for these patients,” said CEO Adeline Perkins.

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) is to report data from a monotherapy expansion component of the study in the first half of 2018. The company also plans to report data from a combination expansion component in the first half of next year.

Infinity Q3 Financial Results

For the three months ended September 30, 2017, Infinity Pharmaceuticals posted a net loss of (-$7.1) million or (-$0.14) million, compared to a net loss of (-$19.5) million reported last year. Revenue in the quarter totaled $6 million related to amounts due from Verastem for the DUO study.

Restructuring activities in the quarter resulted in research and development expenses dropping to $9.3 million, from $12.8 million reported last year. Infinity Pharmaceuticals exited the quarter with cash and cash equivalent of $55.6 million compared to $66.2 million as of June 30, 2016. General and Administrative expenses also dropped because of the restructuring activities to $4.5 million from $7.1 million a year ago.

For the full year, the biopharmaceutical company is projecting a net loss of between $40 million and $50 million. Cash and cash equivalents should range from $40 million and $50 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $INFI and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Avid Technology, Inc. (NASDAQ:AVID)

Avid Technology, Inc. (NASDAQ:AVID) Q3 Earnings Beat Estimates

Avid Technology, Inc. (NASDAQ:AVID)

Shares of Avid Technology, Inc. (NASDAQ:AVID) gained 26.24% after the global media technology company reported better than expected Q3 2017 financial results. Revenues and bookings exceeded guidance in the quarter. Strong improvement in adjusted EBITDA allowed the company to post a fourth consecutive quarter of positive cash flow.

Avid Technology, Inc. (NASDAQ:AVID)

AVID Investors Reaction

Investors reacted to the stellar financial results by pushing the stock from this year’s lows to $5.10 a share. The stock is up by more than 10% for the year. Avid Technology, Inc. (NASDAQ:AVID) faces resistance at the $5.50 mark above which it could make a to this year’s highs of $6 a share.

Renewed investor interest in the stock is as a result of the company exceeding guidance in all its key metrics. According to Chief Executive Officer, Louis Hernandez, Jr., completion of transformation should allow Avid technology to drive profitable growth as well as increase revenue visibility and cash flow.

AVID Q3 Results

For the three months ended September 30, 2017, Avid technology bookings came above the upper end of guidance at $102.8 million. Constant currency bookings totaled $107.9 million which were in line with guidance. GAAP Revenue was $105.3 million above the upper end of guidance. Gross margin came in at 57.3%.

Net income in the quarter came in at $72,000 as adjusted free cash flow came in at $0.5 million at the upper end of the guidance. Adjusted free cash flow for the first nine months rose to $55.7 million,

According to the Chief Executive Officer, customers ranging from the largest media enterprise continue to adopt Avid Technology, Inc. (NASDAQ:AVID)’s innovative solutions.

“With our cloud-enabling MediaCentral platform, enterprises are unlocking greater strategic value from their Avid partnership as we help them to achieve new economies of scale while they work to engage audiences on any device with increasing amounts of content,” said Mr. Hernandez.

Q4 Outlook

During the quarter, Avid Technology, Inc. (NASDAQ:AVID) signed several multi-year enterprise deals with large customers, including Viacom and NHK. Total licenses for the MediaCentral platform increased 27% year-over-year to 51,000. Direct digital bookings with individual creative professionals increased 35% year-over-year.

For the fourth quarter Avid Technology, Inc. (NASDAQ:AVID) expects bookings to range between $118 and $132 million. Revenue, on the other hand, should range between $103 and $113 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AVID and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Zosano Pharma Corp (NASDAQ:ZSAN)

Zosano Pharma Corp (NASDAQ:ZSAN) Q3 Net Loss Widens

Zosano Pharma Corp (NASDAQ:ZSAN)

Zosano Pharma Corp (NASDAQ:ZSAN) shares gained 3.70% after the clinical stage biopharmaceutical company reported financial results and an operational update for Q3 2017. The unveiling of the financial results comes a day after the company initiated long-term safety study of zolmitriptan in migraine patients.

Zosano Pharma Corp (NASDAQ:ZSAN)

Zosano’s Net Loss

Zosano generated a net loss of (-$7.9) million or (-$0.20) a share in the third quarter, a slight increase from a net loss of (-$7.4) million, or (-$0.52) a share, reported last year. It awaits to be seen how investors will react to the wider than expected net loss as the stock continues to trade in a downtrend.

The stock has shed more than 70% in market value since March an underperformance that has plunged it to this year’s lows. Zosano Pharma Corp (NASDAQ:ZSAN) is currently trading near its 52-week low of $0.48 and in dire need of new catalyst if it’s to bounce back.

Research and development expenses in the quarter increased to $5.7 million from $5.1 million reported in Q3 of 2016. General and Administrative expenses remained unchanged at $2 million. Zosano exited the quarter with cash and cash equivalent of $19.8 million debt of $8.2 million and 39.2 million common shares outstanding.

During the quarter, the clinical stage biopharmaceutical company made important strides in the development of its pipeline of drugs. In September, the company presented data from Phase 2/3 ZOTRIP study evaluating M207 as a novel treatment for a migraine.

“The company continues to execute on our path to an NDA, including the initiation of our long-term safety study on November 7 and the continued scale up of manufacturing to support potential commercialization, pending approval of M207 by the FDA,” said CEO, John Walker.

Share Purchase Agreement

Separately, Zosano Pharma Corp (NASDAQ:ZSAN) has entered into a common share purchase agreement with Chicago-based institutional investor, Lincoln Park Capital Fund LLC. Pursuant to the approval of the SEC, the company is to sell shares worth $35 million to the investor.

Under the terms of the agreement, Zosano Pharma Corp (NASDAQ:ZSAN) is to control the timing and the amount of any investment by LPC. The investor will also be required to make purchases based on the purchase agreement and prevailing market prices at the time of each sale.

Zosano Pharma Corp (NASDAQ:ZSAN) plans to use proceeds from the purchase agreement to fund long-term study of its lead product candidate M207, and for general corporate purposes.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ZSAN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ)

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) Q3 Financials Highlight Growth

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ)

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) gained 4.37% after reporting financial results for the three and nine months ended September 30, 2017. According to their Chief Executive officer, Adrian Adams, performance in the quarter underscore strength in underlying business and growth in the U.S and Canada.

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ)

ARLZ Stock Performance

Investors’ confidence on the stock has taken a hit in recent months as seen by the stock trading in a downtrend. Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) is down by more than 50% for the year. It awaits to be seen if the better than expected financial results have what it takes to push the stock higher.

According to Mr. Adams, Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) is on the path to profitability given the performance in third quarter.

“We are delighted with the evolution of Zontivity®, the improved outlook for the Toprol-XL® franchise in the U.S. and the continued strong performance of the Canadian business. As a result of this performance, we updated our 2017 financial guidance and now expect full-year net revenue to be in the range of $95 million to $105 million,” said Mr. Adams.

Aralez Cost Cuts

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) plans to carry out further financial reforms as part of an effort that seeks to accelerate growth heading into the year end. The efforts chould result in a leaner, yet efficient, performance oriented operating model. The improvements are geared towards streaming operations in the U.S with a view of delivering profitability that support growth.

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) plans to trim its Selling, General and Administrative expenses by $32 million or 28%, as part of a cost cutting drive. Expense reductions will include reductions in the amount of money spent on marketing, professional and consulting fees.

Aralez Q3 Financials

Revenues for the three months ended September 30, 2017 totaled $24.3 million nearly double revenues of $13.6 million reported last year. Selling General and Administrative expenses dropped to $24.7 million, from $25.4 million generated in the third quarter of last year.

Net loss in the quarter increased to (-$24.4) million or $0.37 a share, compared to a net loss of (-$20.6) million reported in Q3 2016. Aralez Pharmaceuticals exited the third quarter with cash and cash equivalent of approximately, $40.7 million, sufficient to fund operations over the next 12 months.

Buoyed by the growth phase transition, Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) has revised its full year outlook. The pharmaceutical company now expects revenues of between $95 million and $105 million for the full year, from an initial guidance of between $80 million and $100 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ARLZ and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Smart Sand Inc. (NASDAQ:SND)

Smart Sand Inc. (NASDAQ:SND) Revenues Surge 260%

Smart Sand Inc. (NASDAQ:SND)

Shares of Smart Sand Inc. (NASDAQ:SND) gained 15.12% after the low cost producer of high-quality Northern White raw frac sand reported its best-ever quarter. Revenue for the three months ended September 30, 2017, increased 260% year-over-year, due to higher sales volumes and increased freight revenues.

Smart Sand Inc. (NASDAQ:SND)

According to Chief Executive Officer Charles Young, performance in the quarter underscored the company’s focus on maximizing production and effective management of railcar movements.

“Market demand for our high quality, Northern White frac sand remains strong and we look forward to bringing our additional 2.2 million tons of annual production capacity online by the end of the first quarter of 2018,” said Mr. Adams.

The sentiments appear to have strengthened investors’ confidence in the stock as it continues to bounce back from this year’s low. However, Smart Sand is still trading in a downtrend after losing more than 60% in market value since February.

According to data compiled Zacks Investment Research, Smart Sand Inc. (NASDAQ:SND) is currently rated as a ‘strong buy’ by five Wall St. analyst firms.

Smart Sand Q3 Financial Results

Revenues for the three months ended September 30, 2017 totaled $39.3 million. Smart Sand Inc. (NASDAQ:SND) attributes the 260% increase to customers billed through freight charges as well as increased sales volumes. Revenue in the quarter was also up by 32% compared to the second quarter, due to the higher average selling price.

Smart Sand sold a total of 653,400 tons in the quarter representing a 184% year over year increase from 229,600 tons sold last year. The number of tons sold in the quarter also represented a 23% increase from the second quarter.

Smart Sand Inc. (NASDAQ:SND) generated a net income of $7 million or $0.17 a share in the quarter compared to a net loss of (-$0.1) million reported last year. Adjusted EBITDA totaled $11.4 million nearly triple $4.5 million reported during the third quarter of 2016. Smart Sand attributes the increase to increase in sales volume and higher average selling price per ton.

Capital expenditure in the quarter totaled $19.9 million mostly attributed to expansion works at the Oakdale sand processing facility and investment in various enhancement and cost improvement projects.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SND and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX)

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX)’s Posts Unexpected Net Loss

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX)

Shares of AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) fell 5.13% in after-hours trading on Thursday as investors reacted to the company’s Q3 financial results. A wider than expected net loss for the three and nine months ended September 30, 2017, appears to have spooked investors and fueled a sell-off of the stock.

DSUVIA NDA Woes

Investor confidence on the stock has hit an all-time low in the wake of the U.S. Food and Drug Administration issuing a Complete Response Letter to the company’s new drug, Dsuvia. The stock plunged to a new 52-week low of $1.95 after the regulator rejected a New Drug Application (NDA) for the drug, pending submission of additional safety data.

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) has shed more than 60% in market value over the past one month as investors remain skeptical about Dsuvia prospects following the FDA verdict. Disappointing Q3 financial results could accelerate the stock’s sell-off given that the company has no approved products in the market. Its growth is mostly pegged on the success of its opioid analgesics pipeline which under development.

The specialty Pharmaceutical Company has submitted an application for a Type A meeting with the FDA. The meeting is to be used to shed more light on all the requirements that the company must meet as it eyes DSUVIA NDA resubmission.

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) has already filed a marketing authorization application in Europe.

“DSUVIA remains our core asset as we believe the recommendations in the CRL are manageable. In addition, we successfully completed the ZALVISO Phase 3 study requested by the FDA, and remain focused on providing physicians and patients with non-invasive pain management options for moderate-to-severe acute pain within medically supervised settings,” said CEO, Vince Angotti.

AcelRx Q3 Financial Results

For the three months ended September 30, 2017, AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) generated a net loss of (-$13) million or (-$0.28) a share, compared to a net loss of (-$11.4) million generated last year. Net loss from operations totaled (-$8.9) million compared to (-$8) million during the third quarter of last year. Net Loss for the first nine months of the year increased to (-$41.4) million from (-$33.5) million as of last year.

Revenue in the quarter totaled $1.5 million made up of $1.2 million related to a collaboration with Grunenthal. Revenue for the nine months ended September 30, 2017, totaled $7.2 million. R&D and G&A expenses for the third quarter totaled $8.3 million and $28.4 million for the nine months ended September 30, 2017.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ACRX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Agenus Inc. (NASDAQ:AGEN) Unchanged As Q3 Earnings Meet Estimates

Agenus Inc. (NASDAQ:AGEN)

Shares of Agenus Inc. (NASDAQ:AGEN) traded higher, days after the company reported third quarter financial results that met consensus estimates. The stock was up by 0.29% in Thursday’s trading session to end the day at $3.51 a share.

Agenus Inc. (NASDAQ:AGEN)

AGEN Stock Performance

The stock is currently trading in a downtrend after struggling to close above $4.80. For the full year, the stock is down by more than 10%. Agenus Inc. (NASDAQ:AGEN) faces immediate support at $3.40, below which it could drop to a 52-week low of $3.20 a share.

Investor confidence has taken a hit in recent months. It now awaits to be seen if the third quarter financial results will help reinvigorate investor sentiments going forward. For the three months ended September 30, 2017, the immuno-oncology company reported a net loss of (-$36.8) million or (-$0.37) a share, compared to a net loss of (-$40.8) million reported last year.

Net Loss

For the first nine months of the year, Agenus Inc. (NASDAQ:AGEN) reported a net loss of (-$85.7) million compared to a net loss of (-$100.9) million or (-$1.16) a share reported last year. The decrease in net loss was due to the accelerated milestone payment received from Incyte.

Agenus used a total of $26.2 million in operating activities in the quarter, up from $23.8 million used for the corresponding period last year. Cash and cash equivalent as of the end of the quarter totaled $70.1 million compared to $76.4 million as of December, 31, 2016.

Pipeline Development

The developer of immune checkpoint antibodies and cancer vaccines also achieved significant milestones on the development of its pipeline of drugs.

“We are committed to continuing to innovate having generated several first-in-class and best-in-class immuno-oncology agents; our partnering discussions are maturing on multiple fronts and we expect to close on several business development transactions across our portfolio between now and the end of the first quarter of 2018,” said CEO, Garo Armen.

Agenus Inc. (NASDAQ:AGEN) plans to complete a Phase 1 dose-escalation and generate safety and pharmacodynamics data of AGEN1884 in the fourth quarter. It also plans to commence combination trials of AGEN 1884 and AGEN2034 before the end of the year.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AGEN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Otonomy Inc (NASDAQ:OTIC)

Lots of Good News out for Otonomy Inc (NASDAQ:OTIC)

Otonomy Inc (NASDAQ:OTIC)

Otonomy Inc (NASDAQ:OTIC) released their Q3 earnings after today’s market close and beat analyst expectations. Otonomy posted a net loss of (-$20.99) million, or (-$0.69) per share – versus the consensus forecast of a (-$0.76) EPS loss. Revenues for the quarter came in at $300,000.

Otonomy Inc (NASDAQ:OTIC)

San Diego, CA-based Otonomy Inc (NASDAQ:OTIC) is a biopharmaceutical company that develops and commercializes therapeutics for patients suffering from ear diseases and disorders. FDA-approved OTIPRIO® (ciprofloxacin otic suspension) is used during tympanostomy tube placement surgery in pediatric patients, an sNDA has been accepted for filing by the FDA for acute otitis externa (AOE) and a successful End-of-Phase 2 review has been completed with the FDA for acute otitis media with tympanostomy tubes (AOMT). OTIVIDEXTM is a steroid in development for the treatment of Ménière’s disease.

David A. Weber, Ph.D., president and CEO of Otonomy Inc (NASDAQ:OTIC) said “Today’s announcement of successful results for OTIVIDEX in the AVERTS-2 trial is an important milestone for the company and renews our excitement and commitment to continuing the registration program for OTIVIDEX in Ménière’s disease. We believe that the continuation of OTIVIDEX development for Ménière’s disease and the advancement of our other programs targeting important unmet medical needs including hearing loss and tinnitus provide an attractive path forward for Otonomy.”

Phase 3 Endpoints Met

Otonomy Inc (NASDAQ:OTIC) also announced today that the AVERTS-2 Phase 3 clinical trial of OTIVIDEX in patients with Ménière’s disease achieved its primary efficacy endpoint. The OTIVIDEX group demonstrated a 6.2 day reduction in the mean reported number of DVD from baseline to Month 3 with a 2.5 day mean difference between OTIVIDEX and placebo in Month 3. Otonomy plans to review these results with the U.S. Food and Drug Administration (FDA) and discuss clinical requirements for registration of OTIVIDEX for patients with Ménière’s disease. The company expects to provide an update from discussions with the FDA during the first quarter of 2018.

OTIC Stock Performance

Otonomy Inc (NASDAQ:OTIC) sales were first reported in 2016. That figure was $700,000. Earnings for 2016 were, on a per share basis, reported as a loss of (-$3.69). For the year prior, 2015, the EPS loss was (-$2.58).

The current closing price of $2.80 represents a large discount to the stock’s cash/share value of $4.97 as well as its book/share value of $4.96.

Four investment firms follow Otonomy Inc (NASDAQ:OTIC). Two rate OTIC stock as a “Strong Buy”, while the other two rate the shares as a “Hold”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $OTIC and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.